alnylam
The Director, Clinical Science leads clinical development strategies and trial execution for therapeutic compounds, collaborating with cross-functional teams to ensure successful study design, regulatory submissions, and data review. This role involves providing clinical expertise, managing safety and risk assessments, and supporting audits and inspections. The position requires strong scientific and analytical skills, strategic thinking, and experience in pharmaceutical or biotech clinical research.
Headquarters
Cambridge, Massachusetts, United States
Company Size
1001-5000 employees
Founded
2002
Alnylam is a biopharmaceutical company that has pioneered RNA interference (RNAi) therapeutics, an innovative class of medicines that treats diseases by silencing the genes that cause or contribute to them. The company develops RNAi-based medicines targeting both rare and prevalent diseases across multiple therapeutic areas, with approved products and a robust investigational pipeline. Driven by science and inspired by patients, Alnylam is committed to delivering transformational medicines that address diseases at their genetic source.
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for alnylam.
Director, Clinical Science
Celldex Therapeutics
Associate Director, Clinical Science
Transforming Hypertrophic Cardiomyopathy Care
Director, Clinical Science – Oncology Clinical Development
GSK plc
Senior Clinical Scientist
Aurion Biotech
Senior Manager, Early Clinical Development, Clinical Pharmacology Studies
Bristol Myers Squibb
Director of Clinical Science
Bristol Myers Squibb